GPRC5D Inhibitors
1 drugsAbout GPRC5D
GPRC5D (G-protein coupled receptor family C group 5 member D) is a GPCR protein with expression in certain cancers, making it a potential oncology target. As a cell surface receptor, it can be targeted by antibodies and other modalities.
While there is currently no genetic evidence directly linking GPRC5D to specific diseases, the recent FDA approval of TALVEY validates GPRC5D as a therapeutic target in cancer. Modulating GPRC5D activity has demonstrated therapeutic benefits in cancer treatment.
GPRC5D is currently targeted by one FDA-approved drug, TALVEY (Johnson & Johnson), a bispecific antibody approved in 2023 for oncology indications. Johnson & Johnson is the only company with an approved drug against GPRC5D.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 83% attractiveness score.
- White space opportunity in Waldenstrom Macroglobulinaemia with only 1 trials.
- phase3 represents biological uncertainty with 0% completion.
Top Drugs
Johnson & Johnson is currently the only company with an approved drug targeting GPRC5D.
The lack of competitors indicates high barriers to entry or untapped potential in the GPRC5D space.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets GPRC5D, using bispecific antibody modality.
The modality landscape suggests an opportunity for novel modalities like small molecules or ADCs.
Clinical Trials 54 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 21 | 9 | 0 | 12 | 100% |
| Phase 2 | 22 | 2 | 1 | 19 | 67% |
| Phase 3 | 6 | 1 | 1 | 4 | 50% |
| Phase 4 | 5 | 1 | 1 | 3 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2023 - 2023)
The first and most recent drug approval for GPRC5D was TALVEY in 2023.
The recent approval suggests a growing interest in GPRC5D, but saturation is low.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 46 clinical trials targeting GPRC5D.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities